Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02505919 · ClinicalTrials.gov registry record · NA

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)

A NA study, sponsored by PROCEPT BioRobotics.

Completed
Registry status
NA
Development phase
184
Enrollment target

NCT02505919: Completed NA study, sponsored by PROCEPT BioRobotics.

NCT02505919 is a NA study that has completed, run by PROCEPT BioRobotics. The registered enrollment target is 184 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02505919, a NA study, has completed, sponsored by PROCEPT BioRobotics.

COMPLETED
Registry status
NA
Development phase
184 participants
Enrollment target

Study Summary

A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS). The primary endpoints for safety and effectiveness were measured at 3 and 6 months, respectively, and subjects were followed out to 5 years to collect long-term clinical data.

Primary Outcome

The primary safety endpoint is the proportion of subjects with adverse events rated as probably or definitely related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (e.g. ejaculatory disorder or erectile dysfunction) evidenced through 3 months post treatment. Note that the Clavien-Dindo classification scheme is for grading postoperative complications not events that reflect lack of effective treatment. Results are pres

Interventions

  • DEVICE AQUABEAM System
  • PROCEDURE Transurethral Resection of the Prostate (TURP)

Trial Details

FieldValue
Enrollment Target 184 participants
Start Date 2015-10-30
Est. Completion 2021-12-16
Phase NA
PROCEPT BioRobotics

6 total trials

What the finished NCT02505919 record still lists

NCT02505919 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).

The record links to 0 conditions, and to 2 interventions - of which AQUABEAM System is the first listed.

NCT02505919 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02505919 about?

NCT02505919 is a clinical study titled "Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)". A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS). The primary endpoints for safety and effectiveness were measured at 3 and 6 months, respectively, and subjects were fol...

What is the current status of trial NCT02505919?

This trial is currently completed. It is a NA study. The enrollment target is 184 participants. The study started on 2015-10-30. Estimated completion is 2021-12-16.

What interventions are being tested in trial NCT02505919?

The interventions under investigation include: AQUABEAM System (DEVICE), Transurethral Resection of the Prostate (TURP) (PROCEDURE).

Who is sponsoring clinical trial NCT02505919?

This trial is sponsored by PROCEPT BioRobotics, which has 6 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02505919's enrollment target sits among peer trials

184 581st of 2000 higher than 1,417 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03903510 · 184 participants · NA

    Virtual Reality During Pediatric Cast Removal

  • NCT04020510 · 184 participants · Phase 4

    Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder

  • NCT04135846 · 184 participants · Phase 2

    Alpha-1 Blockade for Alcohol Use Disorder (AUD)

  • NCT04396873 · 184 participants · Phase 1

    PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02505919, the US trial registry maintained by the National Library of Medicine. NCT02505919 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.